[Featured Stocks] GC Green Cross and Hanmi Pharm Increase US FDA Clinical Trial Applications for 'Fabry Disease New Drug'

GC Green Cross and Hanmi Pharmaceutical are both showing strong gains following news that they have submitted a clinical trial application for a Fabry disease new drug to the U.S. Food and Drug Administration (FDA).

As of 10:48 AM on the 1st, Green Cross is trading on the KOSPI market at 142,600 KRW, up 8,900 KRW (6.66%) from the previous close. At the same time, Hanmi Pharmaceutical is also up 6,500 KRW (2.25%) at 295,500 KRW.

During the session, Green Cross reached as high as 142,900 KRW, setting a new 52-week high.

GC Green Cross and Hanmi Pharmaceutical announced that they have submitted an Investigational New Drug (IND) application to the U.S. FDA for the Phase 1/2 clinical trial plan of 'LA-GLA,' a Fabry disease treatment candidate they are jointly developing.

This is an innovative new drug for Fabry disease, jointly developed by the two companies as the world's first monthly once-subcutaneous administration method. Fabry disease is a rare genetic disorder inherited through the sex chromosomes.

This content was produced with the assistance of AI translation services.